key: cord-0750062-96k3pnnw
authors: Mesci, Pinar; Macia, Angela; Saleh, Aurian; Martin-Sancho, Laura; Yin, Xin; Snethlage, Cedric; Avansini, Simoni; Chanda, Sumit K.; Muotri, Alysson
title: Sofosbuvir protects human brain organoids against SARS-CoV-2
date: 2020-05-31
journal: bioRxiv
DOI: 10.1101/2020.05.30.125856
sha: a9727610916353881f4b03f7a1a061810008b085
doc_id: 750062
cord_uid: 96k3pnnw

COVID-19 was rapidly declared a pandemic by the World Health Organization, only three months after the initial outbreak in Wuhan, China. Early clinical care mainly focused on respiratory illnesses. However, a variety of neurological manifestations in both adults and newborns are also emerging. To determine whether SARS-CoV-2 could target the human brain, we infected iPSC-derived human brain organoids. Our findings show that SARS-CoV-2 was able to infect and kill neural cells, including cortical neurons. This phenotype was accompanied by impaired synaptogenesis. Finally, Sofosbuvir, an FDA-approved antiviral drug, was able to rescue these alterations. Given that there are currently no vaccine or antiviral treatments available, urgent therapies are needed. Our findings put Sofosbuvir forward as a potential treatment to alleviate COVID-19-related neurological symptoms. One Sentence Summary SARS-CoV-2 infection causes neuronal death and impaired synaptogenesis, both rescued by Sofosbuvir treatment.

Coronavirus disease 2019 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 or SARS-CoV-2, was declared a pandemic by the World Health Organization on March 11, 2020 . The outbreak first began in Wuhan, China, in December 2019 and quickly spread to 216 countries in 5 months with more than five million cases and more than 330,000 confirmed deaths worldwide. There are now more than one and a half million confirmed cases in the United States, with deaths nearing 100,000 as of May 24, 2020 . With no vaccines, approved treatments, and a high infectivity rate, COVID-19 quickly became a public health emergency worldwide, leading to lockdowns in many areas of the world severely affecting daily life.

As the situation has been developing rapidly, early studies mainly focused on the respiratory component of COVID-19 disease. However, as more cases appear, other COVID-19related clinical manifestations have been reported. Indeed, some COVID-19 adult patients presented with several other neurological symptoms including stroke, hallucinations, epilepsy, encephalopathy, anosmia or ageusia, suggesting that SARS-CoV-2 could impact the central nervous system (1-6). Other neurological manifestations will likely surface in the near future.

Miscarriages and premature births to COVID-19-positive pregnant women have also been reported (7) (8) (9) . Recently, a study showed that placentas from COVID-19-positive pregnant women displayed injury (10) . Finally, SARS-CoV-2 was also detected in semen (11) . Altogether, these findings support the possibility of vertical transmission of the virus to the fetus and potentially affect brain development (12) . Supporting this hypothesis, babies born to SARS-CoV-2-positive mothers have shown several inflammatory symptoms such as neonatal sepsis, rashes, eye infections with long-term impacts remaining unclear (8) . However, there is no experimental evidence that demonstrates that the Sars-CoV-2 virus can infect and impact human brain cells.

Our laboratory previously revealed a causative link between the circulating Brazilian Zika virus and the severe microcephaly observed in babies born from infected mothers using human induced pluripotent stem cell (hiPSC)-derived brain organoids (13) . Human brain organoids are scaled down, three-dimensional models of the brain, recapitulating several molecular and cellular aspects of human embryonic and fetal stages (14) . Brain cortical functional organoids closely mimicked the early stages of human neurodevelopment and network 4 formation (15) . Here, we tested whether SARS-CoV-2 could infect the developing human brain and whether the FDA-approved antiviral drug, Sofosbuvir, could be considered a potential treatment.

Angiotensin-converting enzyme-2 (ACE2) is a critical receptor for SARS-CoV-2; hence its expression has been used to predict the potential vulnerability of different cell types (16) . We generated eight-week-old human brain cortical organoids from healthy donors that contain neural precursor cells (Nestin + , NPC), cortical neurons (MAP2 + ), and astrocytes (GFAP + ) (Fig. 1A) . We found that ACE2 receptors are expressed in human iPSC-derived brain cortical organoids, neurons, astrocytes but not microglia (Fig. 1B) . Next, brain cortical organoids were infected with a SARS-CoV-2 isolate obtained from a patient in Washington State at a multiplicity of infection (MOI) of 2.5. Brain cortical organoids were then assessed by immunolabeling one-week postinfection. Both TUNEL and cleaved caspase 3 (CC3)-integrated signal density were significantly increased by 20-and 5-fold respectively in organoids infected with SARS-CoV-2 compared to mock-infected ones ( Fig.1C-D) . TUNEL and CC3 increased signals were accompanied by a rise in the staining of the SARS-CoV-2 virus by 10-fold compared to mock conditions (Fig.1E ).

We next examined which cell type was preferentially targeted and susceptible to infection with SARS-CoV-2 ( Fig.1-2 ). Eight-week-old organoids contain mostly NPC, neurons, and few astrocytes (15), (Fig 1A) . Therefore, we studied cell death within each of these cell populations.

NPCs showed a 30-fold increase in cell death measured by TUNEL ( Fig.1F -G), accompanied by an accumulation of SARS-CoV-2 within Nestin + NPCs (Fig. 1H ). Next, we studied cell death and viral accumulation in GFAP+ astrocytes ( Fig Given that SARS-CoV-2 could infect MAP2 + post-mitotic neurons, we wondered whether the infection could also affect synaptogenesis. To assess the impact on synaptogenesis, we quantified the number of excitatory synapses in brain organoids using vGLUT1 antibodies (Fig2G-H). The pre-synaptic protein vGLUT1 was significantly decreased by 70 % upon infection with SARS-CoV-2 compared to mock-conditions (Fig.2H ). 5 We previously used brain organoids to repurpose drugs for several neurological conditions (17) (18) (19) (20) . Here, we tested Sofosbuvir efficacy in blocking SARS-CoV-2-induced neurotoxicity. Sofosbuvir (Sovaldi, Gilead Sciences) is an FDA-approved anti-hepatitis C treatment that blocks HCV replication by inhibiting its RNA-dependent RNA polymerase (RdRp). Sofosbuvir can also suppress other viral families of single-stranded, positive-sense RNA viruses, of which Coronaviruses belong to (19, 21) . The SARS-CoV-2 RdRp shares high sequence and structural homology with HCV, supporting the likelihood of inhibiting SARS-CoV-2 with similar efficiency, therefore, we hypothesized that Sofosbuvir could inhibit SARS-CoV-2 RdRp, preventing neuronal death. We determined the safe treatment dosage for brain organoids for Sofosbuvir based on our previous study (19) . We found that treating the organoids twice a week with 20µM Sofosbuvir post-infection, successfully decreased the amount of neuronal cell death and viral accumulation in brain organoids (Fig1C-H, Fig2) . Moreover, we also show that Sofosbuvir restored vGLUT1 protein expression in synaptic puncta (Fig2G, H).

The immediate and long-term lasting neurological and neuropsychiatric sequelae of COVID-19 is currently surfacing. It might take several years to document the survivor's cognitive and mental health burden of recovered COVID-19 cases (22) . Our findings show that SARS-CoV-2 can infect different cell types in human cortical organoids, including postmitotic neurons.

Moreover, SARS-CoV-2 rapidly decreased the amount of the excitatory synapses in cortical neurons, revealing a potential mechanism for the associated neurological symptoms with COVID-19. Our data provide direct experimental evidence that the developing human brain is susceptible to SARS-CoV-2 infections, likely leading to long-term impairments in neuronal function in babies born from COVID-19-positive mothers. In the absence of a vaccine, efficient drug treatment for COVID-19 is urgently in need. We show that the observed neurological impairments in infected brain organoids are rescued by Sofosbuvir treatment, a brain-penetrant FDA-approved drug (23) . Supporting our findings, Sofosbuvir has been pointed as a potential treatment against COVID-19 based on in silico modeling (24) . Thus, treatment with Sofosbuvir could arrest or prevent the development of neurological symptoms in COVID-19 adults.

Sofosbuvir is also an option to block vertical transmission from SARS-CoV-2-infected pregnantwomen for whom prevention is no longer an option. Although further clinical studies are needed, we provide initial evidence that Sofosbuvir is an immediate candidate to pharmacologically treat neurological manifestations related to COVID-19. 

Brain cortical organoids, hiPSC-derived microglia, astrocyte and neurons were generated as previously described (15, 17, 25) and total RNA was extracted using RNeasy Qiagen Mini kit according to manufacturer's instructions. RNAseq was performed in a Illumina HiSeq4000. Data was analyzed by Rosalind ((https://rosalind.onramp.bio/), an online platform for data analyses, as previously described (18) . Cell culture 13 iPSCs were cultured and manually passaged onto Matrigel-coated (Corning) and fed daily with mTESR1 (StemCell Technologies).

iPSCs-derived brain cortical organoids were differentiated as previously described (Trujillo et al., 2019) . Briefly, iPSCs were dissociated using a 1:1 Dulbecco's phosphate- All the cell lines tested negative for mycoplasma contamination. All cell lines used have been authenticated.

Brain cortical organoids were infected with 750,000 PFU that correspond to a MOI of 2.5

considering an average of 300,000 cells per organoid on day 52 of differentiation and left in culture for three days in maintenance media. Fresh media was added atop and kept in suspension 15 secondaries, as shown above. Images were blindly collected using an Axio Observer Z1

Microscope with ApoTome (Zeiss) and analyzed with ImageJ software. To calculate the integrated density, the channels were split and the fluorescence corresponding to each staining was measured by Image J software.

Results were analyzed using Prism Software (version 6, GraphPad, USA). Statistical significance was determined using one-way ANOVA tests followed by Tukey or Sidak multiple 

Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients

Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?

Anosmia and Ageusia: Common Findings in COVID-19 Patients

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review

Central nervous system manifestations of COVID-19: A systematic review

Effects of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcomes: a systematic review

Coronavirus in pregnancy and delivery: rapid review

Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and metaanalysis

Placental Pathology in COVID-19

Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease

Possible Vertical Transmission of SARS-CoV-2 from an Infected Mother to Her Newborn

The Brazilian Zika virus strain causes birth defects in experimental models

Brain organoids as tools for modeling human neurodevelopmental disorders

Complex Oscillatory Waves Emerging from Cortical Organoids Model Early Human Brain Network Development

Structural basis of receptor recognition by SARS-CoV-2

Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation

Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin α vβ5 Axis

Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

Survivors' burden. Science (80-. )

Sofosbuvir: A novel treatment option for chronic hepatitis C infection

SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective

Modeling neuro-immune interactions during Zika virus infection

paraformaldehyde (PFA) solution, and further embedded in 30% sucrose for 24 hours. Tissue was placed in a mold for cryosectioning and covered with a layer of optimal cutting temperature

Primary antibodies were diluted with blocking solution and incubated with cells overnight at 4°C: Cleaved caspase-3 (rabbit

Sino Biological #40143-R019, 1: 2000) was incubated diluted with blocking solution and incubated with cells for 20 minutes at room temperature. Cells were then washed twice with 1xPBS and incubated with the secondary antibody for 30 minutes at room temperature

555 and 647) were purchased from Life Technologies and used at a 1:1000 dilution. After the 30 minutes incubation, samples were washed twice (1xPBS), incubated for 5 minutes with fluorescent nuclear DAPI stain (VWR; 1:10000), and mounted with Slow fade gold antifade reagent (Life Technologies). Samples were imaged using an Axio Observer Z1

For TUNEL analysis, samples were fixed with 4% paraformaldehyde and permeabilized with 0.25% Triton X-100 for 15 minutes and then stained for TUNEL following manufacturer's instructions (Click-iT TUNEL assay kit from Life Technologies). Cells were blocked with 3% BSA for 1 hour and then